MA56416A - Détermination de la pureté de protéines multimériques - Google Patents

Détermination de la pureté de protéines multimériques

Info

Publication number
MA56416A
MA56416A MA056416A MA56416A MA56416A MA 56416 A MA56416 A MA 56416A MA 056416 A MA056416 A MA 056416A MA 56416 A MA56416 A MA 56416A MA 56416 A MA56416 A MA 56416A
Authority
MA
Morocco
Prior art keywords
multimeric proteins
purity determination
purity
determination
multimeric
Prior art date
Application number
MA056416A
Other languages
English (en)
French (fr)
Inventor
Jiann-Kae Luo
Kathir Muthusamy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA56416A publication Critical patent/MA56416A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2201/00—Features of devices classified in G01N21/00
    • G01N2201/06—Illumination; Optics
    • G01N2201/061—Sources
    • G01N2201/06113—Coherent sources; lasers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44717—Arrangements for investigating the separated zones, e.g. localising zones
    • G01N27/44721—Arrangements for investigating the separated zones, e.g. localising zones by optical means
    • G01N27/44726—Arrangements for investigating the separated zones, e.g. localising zones by optical means using specific dyes, markers or binding molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G01N27/44795—Isoelectric focusing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA056416A 2015-05-12 2016-05-11 Détermination de la pureté de protéines multimériques MA56416A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562160341P 2015-05-12 2015-05-12

Publications (1)

Publication Number Publication Date
MA56416A true MA56416A (fr) 2022-05-04

Family

ID=56072452

Family Applications (2)

Application Number Title Priority Date Filing Date
MA056416A MA56416A (fr) 2015-05-12 2016-05-11 Détermination de la pureté de protéines multimériques
MA043987A MA43987A (fr) 2015-05-12 2016-05-11 Détermination de la pureté de protéine multimère

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA043987A MA43987A (fr) 2015-05-12 2016-05-11 Détermination de la pureté de protéine multimère

Country Status (10)

Country Link
US (3) US10520511B2 (cg-RX-API-DMAC7.html)
EP (2) EP3294775B1 (cg-RX-API-DMAC7.html)
JP (3) JP7240812B2 (cg-RX-API-DMAC7.html)
AR (1) AR104610A1 (cg-RX-API-DMAC7.html)
AU (2) AU2016261854B2 (cg-RX-API-DMAC7.html)
CA (1) CA2984010A1 (cg-RX-API-DMAC7.html)
ES (1) ES2881359T3 (cg-RX-API-DMAC7.html)
MA (2) MA56416A (cg-RX-API-DMAC7.html)
PL (1) PL3294775T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016183222A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121253411A (zh) 2015-11-30 2026-01-02 因塔生物有限责任公司 用于样品表征的装置和方法
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
MY199833A (en) 2017-08-17 2023-11-24 Just Evotec Biologics Inc Method of purifying glycosylated protein from host cell galectins and other contaminants
MY202872A (en) 2017-11-20 2024-05-28 Just Evotec Biologics Inc Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
CA3089842A1 (en) 2018-01-29 2019-08-01 Intabio, Inc. Devices, methods and kits for sample characterization
EP3811397B1 (en) 2018-05-31 2024-09-18 Intabio, Llc Methods for interfacing microfluidic systems with mass spectrometry
WO2020055832A1 (en) * 2018-09-10 2020-03-19 Genentech, Inc. Systems and methods for affinity capillary electrophoresis
US11782023B2 (en) * 2018-12-19 2023-10-10 Regeneron Pharmaceuticals, Inc. Ce-western applications for antibody development
CA3126712A1 (en) * 2019-01-31 2020-08-06 Regeneron Pharmaceuticals, Inc. Native microfluidic ce-ms analysis of antibody charge heterogeneity
US12594557B2 (en) 2019-08-12 2026-04-07 Intabio, Llc Isoelectric focusing devices and fixtures
US11285484B2 (en) 2019-08-12 2022-03-29 Intabio, Llc Multichannel isoelectric focusing devices and high voltage power supplies
JP2024513950A (ja) * 2021-04-14 2024-03-27 ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド キャピラリー電気泳動におけるタンパク質分析のための天然蛍光検出
CN118284809A (zh) * 2021-11-25 2024-07-02 豪夫迈·罗氏有限公司 少量抗体副产物的定量
WO2024123698A1 (en) * 2022-12-08 2024-06-13 Regeneron Pharmaceuticals, Inc. Methods to characterizing a fragment crystallizable domain of a bispecific antibody

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP385598A0 (en) * 1998-06-02 1998-06-25 Life Therapeutics Limited Purification of antibodies
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6818112B2 (en) * 1999-04-20 2004-11-16 Target Discovery, Inc. Protein separation via multidimensional electrophoresis
JP4723725B2 (ja) * 1999-04-20 2011-07-13 ターゲット ディスカバリー, インコーポレイテッド 代謝経路を分析するための方法
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
AUPQ743300A0 (en) * 2000-05-11 2000-06-01 Life Therapeutics Limited Separation of avian antibodies
US6927004B2 (en) 2002-03-08 2005-08-09 Asml Netherlands B.V. Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
WO2007034907A1 (ja) * 2005-09-22 2007-03-29 Chemicals Evaluation And Research Institute 被検化学物質の生物に与える影響の予測方法
EP1803814A1 (en) * 2005-12-27 2007-07-04 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Method of improving the antibody selection capacity in phage-display library
JP5144499B2 (ja) * 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
DK2150617T3 (en) 2007-06-04 2015-01-12 Regeneron Pharma Regions with increased expression and stability
EP3127921A1 (en) * 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
JP4977588B2 (ja) * 2007-12-07 2012-07-18 富士フイルム株式会社 イムノクロマトグラフ方法
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US9376495B2 (en) * 2011-05-21 2016-06-28 Macrogenics, Inc. Deimmunized serum-binding domains and their use in extending serum half-life
GB2504139B (en) * 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
EP2604624A1 (en) * 2011-12-13 2013-06-19 University College Dublin National University Of Ireland, Dublin Bowman-Birk protease Inhibitor (BBI) binding peptides, and uses thereof in the separation, detection or purification of BBI.
EP3517548A1 (en) * 2012-03-13 2019-07-31 NovImmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
SG10201609535TA (en) 2012-06-05 2017-01-27 Regeneron Pharma Methods for making fully human bispecific antibodies using a common light chain
TWI864338B (zh) 2012-11-14 2024-12-01 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
CN118271429A (zh) * 2013-08-19 2024-07-02 豪夫迈·罗氏有限公司 用羟基磷灰石层析分离双特异性抗体和双特异性抗体生产副产物
EP3041865A2 (en) * 2013-09-03 2016-07-13 NovImmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions

Also Published As

Publication number Publication date
MA43987A (fr) 2018-12-19
US20240280587A1 (en) 2024-08-22
AU2022203033B2 (en) 2025-06-26
WO2016183222A4 (en) 2017-01-05
AU2022203033A1 (en) 2022-05-26
CA2984010A1 (en) 2016-11-17
ES2881359T3 (es) 2021-11-29
US10520511B2 (en) 2019-12-31
US12158473B2 (en) 2024-12-03
JP7137663B2 (ja) 2022-09-14
HK1252480A1 (zh) 2019-05-24
AU2016261854A1 (en) 2017-11-09
EP3885368A1 (en) 2021-09-29
JP2021152544A (ja) 2021-09-30
EP3294775B1 (en) 2021-07-14
JP2022171730A (ja) 2022-11-11
US20170045527A1 (en) 2017-02-16
AU2016261854B2 (en) 2022-05-26
JP7240812B2 (ja) 2023-03-16
US20200166522A1 (en) 2020-05-28
AR104610A1 (es) 2017-08-02
EP3294775A1 (en) 2018-03-21
WO2016183222A1 (en) 2016-11-17
PL3294775T3 (pl) 2021-12-13
JP2018528389A (ja) 2018-09-27

Similar Documents

Publication Publication Date Title
IL254516B (en) Proteins specific for cd137
EP3397764A4 (en) DIGITAL PROTEIN QUANTIFICATION
MA43987A (fr) Détermination de la pureté de protéine multimère
DK3292141T3 (da) Fusionsproteiner
EP3362556C0 (en) POLYPEPTIDE VARIANTS
DK3197453T3 (da) Kimært protein
EP3191599C0 (en) DETECTION OF MISFOLDED PROTEINS
DE112015006591B8 (de) Stromsensor
EP2976352A4 (en) CLEANING OF TRIPELHELIC PROTEINS
EP3333331A4 (en) BUILDING STRUCTURE FOR MODULAR CONTAINERHAUS
GB201518792D0 (en) Production of proteins
EP3360010A4 (en) BI PHOTONS WITH VOTABLE SOURCE
EP3344278A4 (en) INSULIN-IMMUNOGLOBULIN FUSION PROTEINS
LT3237432T (lt) Baltymo gamyba
EP3406336A4 (en) NANO FOIL OF CORE CASE STRUCTURE TYPE
DK3730511T3 (da) Proteinoprensning
DK3259358T3 (da) Forøget proteinekspression
EP3356516A4 (en) CULTIVATION OF HUMAN NOROVIRES
EP3471544A4 (en) MODIFIED DYSTROPHIN PROTEINS
EP3436049A4 (en) ANGIOPOIETIN-SIMILAR PROTEIN 8 (ANGPTL8)
EP3464384A4 (en) FUSION PRODUCT CONSTRUCT
HRP20182029T1 (hr) Uti-fuzijski proteini
IL257887A (en) Expression of fc-containing proteins
EP3277701A4 (en) SYNTHESIS OF DESOSAMINES
IL254502A0 (en) Solid forms of menaquinols